News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ACT Biotech to Present Significant Progress in Stomach Cancer Treatment at American Society of Clinical Oncology



5/19/2011 10:00:20 AM

SAN FRANCISCO, May 19, 2011 (GLOBE NEWSWIRE) -- ACT BIOTECH, Inc today announced that it will present encouraging results on the telatinib Phase 2 clinical trial in patients with advanced stomach cancer. Data from the front-line treatment study will be presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting taking place June 3 through June 7, 2011, in Chicago, Illinois.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES